Curis, Inc., a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CRIS
Previous Symbol
CUSIP23126910
Phone617-503-6500
Debt
Debt-to-Equity Ratio38.74
Current Ratio2.63
Quick Ratio2.63
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$9.90 million
Price / Sales2.81
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.73 per share
Price / Book1.15
Profitability
EPS (Most Recent Fiscal Year)($1.80)
Net Income$-53,310,000.00
Net Margins-316.98%
Return on Equity-299.20%
Return on Assets-59.60%
Miscellaneous
Employees55
Outstanding Shares33,110,000
Market Cap$26.49 million
OptionableOptionable
Curis (NASDAQ:CRIS) Frequently Asked Questions
What is Curis' stock symbol?
Curis trades on the NASDAQ under the ticker symbol "CRIS."
When did Curis' stock split? How did Curis' stock split work?
Shares of Curis reverse split on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 29th 2018. An investor that had 100 shares of Curis stock prior to the reverse split would have 20 shares after the split.
How were Curis' earnings last quarter?
Curis, Inc. (NASDAQ:CRIS) posted its quarterly earnings data on Thursday, November, 1st. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.09. The biotechnology company earned $2.85 million during the quarter, compared to analysts' expectations of $2.38 million. Curis had a negative net margin of 316.98% and a negative return on equity of 299.20%. View Curis' Earnings History.
When is Curis' next earnings date?
What price target have analysts set for CRIS?
3 brokerages have issued twelve-month price targets for Curis' stock. Their predictions range from $8.00 to $30.00. On average, they anticipate Curis' share price to reach $19.00 in the next year. This suggests a possible upside of 2,162.2% from the stock's current price. View Analyst Price Targets for Curis.
What is the consensus analysts' recommendation for Curis?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Curis.
Has Curis been receiving favorable news coverage?
Media headlines about CRIS stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Curis earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the next several days.
Are investors shorting Curis?
Curis saw a increase in short interest in November. As of November 15th, there was short interest totalling 1,276,538 shares, an increase of 39.6% from the October 31st total of 914,102 shares. Based on an average daily volume of 325,109 shares, the days-to-cover ratio is currently 3.9 days. Currently, 4.7% of the shares of the company are short sold. View Curis' Current Options Chain.
Who are some of Curis' key competitors?
Some companies that are related to Curis include Pluristem Therapeutics (PSTI), Aptose Biosciences (APTO), Cidara Therapeutics (CDTX), Aevi Genomic Medicine (GNMX), BioCardia (BCDA), Brainstorm Cell Therapeutics (BCLI), Applied Genetic Technologies (AGTC), Arsanis (ASNS), Entera Bio (ENTX), Genocea Biosciences (GNCA), Oncobiologics (ONS), AVITA MED LTD/S (AVMXY), Proteon Therapeutics (PRTO), BIONDVAX PHARMA/S (BVXV) and TRACON Pharmaceuticals (TCON).
Who are Curis' key executives?
Curis' management team includes the folowing people:
- Mr. James E. Dentzer, Pres, CEO, COO, CFO, Chief Admin. Officer & Director (Age 51)
- Dr. David Tuck, Sr. VP & Chief Medical Officer (Age 66)
- Mr. Mark W. Noel, VP of Technology Management & Intellectual Property (Age 59)
- Mr. Bill Steinkrauss, Corp. Controller & Sr. Director of Fin.
- Dr. Tania Chander, VP of Product Devel. & Program Management
Who are Curis' major shareholders?
Curis' stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc (3.30%), Renaissance Technologies LLC (1.87%) and JPMorgan Chase & Co. (0.22%). Company insiders that own Curis stock include Ali PhD Fattaey, James R Mcnab and Marc Rubin. View Institutional Ownership Trends for Curis.
Which major investors are selling Curis stock?
Which major investors are buying Curis stock?
CRIS stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and JPMorgan Chase & Co.. Company insiders that have bought Curis stock in the last two years include Ali PhD Fattaey and Marc Rubin. View Insider Buying and Selling for Curis.
How do I buy shares of Curis?
Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Curis' stock price today?
One share of CRIS stock can currently be purchased for approximately $0.8399.
How big of a company is Curis?
Curis has a market capitalization of $26.49 million and generates $9.90 million in revenue each year. The biotechnology company earns $-53,310,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Curis employs 55 workers across the globe.
What is Curis' official website?
How can I contact Curis?
Curis' mailing address is 4 MAGUIRE ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected]
MarketBeat Community Rating for Curis (NASDAQ CRIS)
MarketBeat's community ratings are surveys of what our community members think about Curis and other stocks. Vote "Outperform" if you believe CRIS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRIS will underperform the S&P 500 over the long term. You may vote once every thirty days.
